1256 related articles for article (PubMed ID: 8821512)
1. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding.
Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors.
Burges RA; Gardiner DG; Gwilt M; Higgins AJ; Blackburn KJ; Campbell SF; Cross PE; Stubbs JK
J Cardiovasc Pharmacol; 1987 Jan; 9(1):110-9. PubMed ID: 2434785
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
5. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue.
Brixius K; Gross T; Tossios P; Geissler HJ; Mehlhorn U; Schwinger RH; Hekmat K
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):708-13. PubMed ID: 16173926
[TBL] [Abstract][Full Text] [Related]
6. Comparison of binding affinities and negative inotropic potencies of the 1,4-dihydropyridine calcium channel blockers in rabbit myocardium.
Boyd RA; Giacomini JC; Wong FM; Nelson WL; Giacomini KM
J Pharmacol Exp Ther; 1987 Oct; 243(1):118-25. PubMed ID: 2822893
[TBL] [Abstract][Full Text] [Related]
7. Structurally novel antihypertensive compound, McN-5691, is a calcium channel blocker in vascular smooth muscle.
Flaim SF; Gleason MM; Hedberg A; Shank RP; McCullough JR; Gill A; Damiano BP; Brannan MD; Carson JR
J Pharmacol Exp Ther; 1991 Jan; 256(1):279-88. PubMed ID: 1846419
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
[TBL] [Abstract][Full Text] [Related]
9. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604
[TBL] [Abstract][Full Text] [Related]
10. Tiapamil, a new calcium antagonist. 1. Demonstration of calcium antagonistic activity and related studies.
Eigenmann R; Blaber L; Nakamura K; Thorens S; Haeusler G
Arzneimittelforschung; 1981; 31(9):1393-401. PubMed ID: 7197945
[TBL] [Abstract][Full Text] [Related]
11. Excitation-contraction coupling in cardiac and vascular smooth muscle: modification by calcium-entry blockade.
McCall D
Circulation; 1987 Jun; 75(6 Pt 2):V3-14. PubMed ID: 2436829
[TBL] [Abstract][Full Text] [Related]
12. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Nielsen-Kudsk JE
Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
[TBL] [Abstract][Full Text] [Related]
13. PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta.
Hof RP; Scholtysik G; Loutzenhiser R; Vuorela HJ; Neumann P
J Cardiovasc Pharmacol; 1984; 6(3):399-406. PubMed ID: 6202964
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitory action of Biginelli-type dihydropyrimidines on depolarization-induced arterial smooth muscle contraction.
Cernecka H; Veizerova L; Mensikova L; Svetlik J; Krenek P
J Pharm Pharmacol; 2012 May; 64(5):735-41. PubMed ID: 22471370
[TBL] [Abstract][Full Text] [Related]
15. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
[TBL] [Abstract][Full Text] [Related]
16. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.
Angelico P; Guarneri L; Leonardi A; Testa R
J Pharm Pharmacol; 1999 Jun; 51(6):709-14. PubMed ID: 10454048
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey.
Nakajima M; Adachi I; Ueda M
Arzneimittelforschung; 1993 Dec; 43(12):1276-82. PubMed ID: 8141814
[TBL] [Abstract][Full Text] [Related]
18. Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies.
Micheli D; Collodel A; Semeraro C; Gaviraghi G; Carpi C
J Cardiovasc Pharmacol; 1990 Apr; 15(4):666-75. PubMed ID: 1691398
[TBL] [Abstract][Full Text] [Related]
19. Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 312():86-103. PubMed ID: 1663336
[TBL] [Abstract][Full Text] [Related]
20. Effects of terflavoxate on stimulated contractions of urinary bladder in vitro.
Testa R; Guarneri L; Bernasconi P; Angelico P; Ibba M; Poggesi E; Meli A
Arzneimittelforschung; 1993 Feb; 43(2):122-8. PubMed ID: 8384453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
